MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a Rockville, MD-based cell-engineering centered firm, introduced the acquisition of SeQure Dx, a Waltham, MA-based market chief of on-target and off-target modifying evaluation companies for cell and gene therapies.
Below the phrases of the settlement, Maxcyte paid a complete preliminary consideration of $4.5 million at closing in money for the complete issued share capital of SeQure DX on a money free, debt free foundation utilizing Maxcyte’s current money sources. A further quantity, that won’t exceed $2.5 million, could also be paid in contingent consideration if the corporate exceeds sure income targets. In 2024 (primarily based on obtainable unaudited outcomes from January 1 via November 30), SeQure DX incurred income of roughly $1.7 million and a lack of roughly $6.5 million and has internet belongings of $0.7 million as of closing.
This strategic acquisition strengthens MaxCyte’s means to serve ex vivo and in vivo cell and gene remedy (CGT) builders with an revolutionary suite of instruments and companies spanning early R&D via medical growth and commercialization.
Safe Dx is an organization which focuses on gene modifying security analytics, devoted to advancing cell and gene therapies from discovery to affected person. It supplies complete off-target danger evaluation options for gene modifying, spanning from early discovery via IND submission.
Led by CEO Maher Masoud, MaxCyte is a cell-engineering centered firm offering options to advance the invention, growth and commercialization of recent cell therapeutics.
FinSMEs
30/01/2025
